TABLE OF CONTENTS
1 INTRODUCTION
1.1 MARKET DEFINITION
1.2 MARKET SEGMENTATION
1.3 RESEARCH TIMELINES
1.4 ASSUMPTIONS
1.5 LIMITATIONS
2 RESEARCH METHODOLOGY
2.1 DATA MINING
2.2 SECONDARY RESEARCH
2.3 PRIMARY RESEARCH
2.4 SUBJECT MATTER EXPERT ADVICE
2.5 QUALITY CHECK
2.6 FINAL REVIEW
2.7 DATA TRIANGULATION
2.8 BOTTOM-UP APPROACH
2.9 TOP-DOWN APPROACH
2.10 RESEARCH FLOW
3 EXECUTIVE SUMMARY
3.1 MARKET OVERVIEW
3.2 U.S. AUTISM SPECTRUM DISORDER MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
3.3 U.S. AUTISM SPECTRUM DISORDER MARKET, BY AGE (USD MILLION)
3.4 U.S. AUTISM SPECTRUM DISORDER MARKET, BY AUTISM TYPE (USD MILLION)
3.5 U.S. AUTISM SPECTRUM DISORDER MARKET, BY TREATMENT TYPE (USD MILLION)
3.6 FUTURE MARKET OPPORTUNITIES
3.7 U.S. MARKET SPLIT
4 MARKET OUTLOOK
4.1 U.S. AUTISM SPECTRUM DISORDER MARKET OUTLOOK
4.2 MARKET DRIVERS
4.2.1 RISING PREVALENCE OF PATIENTS SUFFERING FROM ASD
4.2.2 GROWING AWARENESS AND INITIATIVE PROGRAMS
4.2.3 INCREASING GOVERNMENT FUNDING
4.3 MARKET RESTRAINT
4.3.1 HIGH ASD-ASSOCIATED DIRECT COSTS
4.4 MARKET OPPORTUNITY
4.4.1 ONGOING CLINICAL TRIALS AND RESEARCH STUDIES
4.5 IMPACT OF COVID-19 ON U.S. AUTISM SPECTRUM DISORDERS MARKET
4.6 PORTER’S FIVE FORCES ANALYSIS
4.7 MARKET DYNAMIC FOR PENNSYLVANIA
4.8 PERCENT OF INDIVIDUALS WITH AUTISM IN PENNSYLVANIA BY AGE GROUP
5 MARKET, BY AGE
5.1 OVERVIEW
5.2 CHILD (BIRTH - 21 YEARS)
5.3 ADULT (21+ YEARS)
6 MARKET, BY TYPE
6.1 OVERVIEW
6.2 AUTISTIC DISORDER
6.3 PERVASIVE DEVELOPMENTAL DISORDER
6.4 ASPERGER SYNDROME
6.5 CHILDHOOD DISINTEGRATIVE DISORDER
7 MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 BEHAVIORAL APPROACHES
7.3 EARLY INTERVENTION
7.4 DRUG THERAPY
7.5 DIETARY APPROACH
7.6 OTHER
8 MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 PENNSYLVANIA
8.3 CALIFORNIA
8.4 TEXAS
8.5 NEW YORK
8.6 FLORIDA
8.7 ILLINOIS
8.8 OHIO
8.9 GEORGIA
8.10 MICHIGAN
8.11 NEW JERSEY
8.12 REST OF THE U.S.
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPETITIVE SCENARIO
9.3 COMPANY MARKET RANKING ANALYSIS
10 COMPANY PROFILES
10.1 UPMC
10.1.1 COMPANY OVERVIEW
10.1.2 COMPANY INSIGHTS
10.1.3 PRODUCT BENCHMARKING
10.1.4 SWOT ANALYSIS
10.2 THE MAY INSTITUTE
10.2.1 COMPANY OVERVIEW
10.2.2 COMPANY INSIGHTS
10.2.3 PRODUCT BENCHMARKING
10.2.4 SWOT ANALYSIS
10.3 CHANCE LIGHT BEHAVIORAL HEALTH
10.3.1 COMPANY OVERVIEW
10.3.2 COMPANY INSIGHTS
10.3.3 PRODUCT BENCHMARKING
10.3.4 KEY DEVELOPMENT
10.3.5 SWOT ANALYSIS
10.4 MAGELLAN HEALTH, INC.
10.4.1 COMPANY OVERVIEW
10.4.2 COMPANY INSIGHTS
10.4.3 SEGMENT BREAKDOWN
10.4.4 PRODUCT BENCHMARKING
10.4.5 KEY DEVELOPMENT
10.5 VISTA AUTISM SERVICES
10.5.1 COMPANY OVERVIEW
10.5.2 COMPANY INSIGHTS
10.5.3 PRODUCT BENCHMARKING
10.6 OTSUKA HOLDINGS CO. LTD.
10.6.1 COMPANY OVERVIEW
10.6.2 COMPANY INSIGHTS
10.7 ELI LILLY AND COMPANY
10.7.1 COMPANY OVERVIEW
10.7.2 COMPANY INSIGHTS
10.7.1 SEGMENT BREAKDOWN
10.8 PFIZER INC.
10.8.1 COMPANY OVERVIEW
10.8.2 COMPANY INSIGHTS
10.9 JOHNSON & JOHNSON
10.9.1 COMPANY OVERVIEW
10.9.2 COMPANY INSIGHTS
10.9.3 SEGMENT BREAKDOWN
10.9.4 KEY DEVELOPMENT
10.10 AUTISM SPEAKS
10.10.1 COMPANY OVERVIEW
10.10.2 COMPANY INSIGHTS
10.10.3 PRODUCT BENCHMARKING
10.11 CITY PRO GROUP
10.11.1 COMPANY OVERVIEW
10.11.2 COMPANY INSIGHTS
10.11.3 PRODUCT BENCHMARKING
10.12 AUTISM LEARNING PARTNERS
10.12.1 COMPANY OVERVIEW
10.12.2 COMPANY INSIGHTS
10.12.3 PRODUCT BENCHMARKING
10.12.4 KEY DEVELOPMENT
10.13 AUTISM SPECTRUM THERAPIES
10.13.1 COMPANY OVERVIEW
10.13.2 COMPANY INSIGHTS
10.13.3 PRODUCT BENCHMARKING
10.14 BUTTERFLY EFFECTS
10.14.1 COMPANY OVERVIEW
10.14.2 COMPANY INSIGHTS
10.14.3 PRODUCT BENCHMARKING
10.15 CENTRIA AUTISM SERVICES
10.15.1 COMPANY OVERVIEW
10.15.2 COMPANY INSIGHTS
10.15.3 PRODUCT BENCHMARKING
10.16 ALLERGAN
10.16.1 COMPANY OVERVIEW
10.16.2 COMPANY INSIGHTS
10.16.3 PRODUCT BENCHMARKING
10.16.4 KEY DEVELOPMENT
10.17 THE CENTER FOR AUTISM & RELATED DISORDERS
10.17.1 COMPANY OVERVIEW
10.17.2 COMPANY INSIGHTS
10.17.3 PRODUCT BENCHMARKING
LIST OF TABLES
TABLE 1 U.S. AUTISM SPECTRUM DISORDER MARKET, BY AGE, 2021 – 2028 (USD MILLION)
TABLE 2 U.S. AUTISM SPECTRUM DISORDER MARKET, BY AUTISM TYPE, 2021 – 2028 (USD MILLION)
TABLE 3 U.S. AUTISM SPECTRUM DISORDER MARKET, BY TREATMENT TYPE, 2021 – 2028 (USD MILLION)
TABLE 4 U.S. AUTISM SPECTRUM DISORDER MARKET, BY GEOGRAPHY, 2021 – 2028 (USD MILLION)
TABLE 5 PREVALENCE OF AUTISTIC ADULTS IN UNITED STATES
TABLE 1 COMPANY MARKET RANKING ANALYSIS
TABLE 2 UPMC: PRODUCT BENCHMARKING
TABLE 3 THE MAY INSTITUTE: PRODUCT BENCHMARKING
TABLE 4 CHANCE LIGHT BEHAVIORAL HEALTH: PRODUCT BENCHMARKING
TABLE 5 CHANCE LIGHT BEHAVIORAL HEALTH: KEY DEVELOPMENT
TABLE 6 MAGELLAN HEALTH, INC.: PRODUCT BENCHMARKING
TABLE 7 MAGELLAN HEALTH, INC.: KEY DEVELOPMENT
TABLE 8 VISTA AUTISM SERVICES: PRODUCT BENCHMARKING
TABLE 9 JOHNSON & JOHNSON: KEY DEVELOPMENT
TABLE 10 AUTISM SPEAKS: PRODUCT BENCHMARKING
TABLE 11 CITY PRO GROUP: PRODUCT BENCHMARKING
TABLE 12 AUTISM LEARNING PARTNERS: PRODUCT BENCHMARKING
TABLE 13 AUTISM LEARNING PARTNERS: KEY DEVELOPMENT
TABLE 14 AUTISM SPECTRUM THERAPIES: PRODUCT BENCHMARKING
TABLE 15 BUTTERFLY EFFECTS: PRODUCT BENCHMARKING
TABLE 16 CENTRIA AUTISM SERVICES: PRODUCT BENCHMARKING
TABLE 17 ALLERGAN: PRODUCT BENCHMARKING
TABLE 18 ALLERGAN: KEY DEVELOPMENT
TABLE 19 THE CENTER FOR AUTISM & RELATED DISORDERS: PRODUCT BENCHMARKING
LIST OF FIGURES
FIGURE 1 U.S. AUTISM SPECTRUM DISORDER MARKET SEGMENTATION
FIGURE 2 RESEARCH TIMELINES
FIGURE 3 DATA TRIANGULATION
FIGURE 4 MARKET RESEARCH FLOW
FIGURE 5 U.S. AUTISM SPECTRUM DISORDER MARKET OVERVIEW
FIGURE 6 U.S. AUTISM SPECTRUM DISORDER MARKET GEOGRAPHICAL ANALYSIS, 2021-2028
FIGURE 7 U.S. AUTISM SPECTRUM DISORDER MARKET, BY AGE (USD MILLION)
FIGURE 8 U.S. AUTISM SPECTRUM DISORDER MARKET, BY AUTISM TYPE (USD MILLION)
FIGURE 9 U.S. AUTISM SPECTRUM DISORDER MARKET, BY TREATMENT TYPE (USD MILLION)
FIGURE 10 FUTURE MARKET OPPORTUNITIES
FIGURE 11 CALIFORNIA DOMINATED THE MARKET IN 2020
FIGURE 12 U.S. AUTISM SPECTRUM DISORDER MARKET OUTLOOK
FIGURE 13 ESTIMATED AUTISM PREVALENCE 2020
FIGURE 14 PREVALENCE RATE BY STATE, 2016
FIGURE 15 PORTER’S FIVE FORCES ANALYSIS OF U.S. AUTISM SPECTRUM DISORDERS MARKET
FIGURE 16 NUMBER OF INDIVIDUALS DIAGNOSED WITH AUTISM IN PENNSYLVANIA >= 21 YEARS OF AGE
FIGURE 17 PERCENT OF INDIVIDUALS WITH AUTISM IN PENNSYLVANIA BY AGE GROUP
FIGURE 18 U.S. AUTISM SPECTRUM DISORDER MARKET, BY AGE
FIGURE 19 U.S. AUTISM SPECTRUM DISORDER MARKET, BY AUTISM TYPE
FIGURE 20 U.S. AUTISM SPECTRUM DISORDER MARKET, BY TREATMENT TYPE
FIGURE 21 THE U.S. AUTISM SPECTRUM DISORDER MARKET SNAPSHOT
FIGURE 22 U.S. AUTISM SPECTRUM DISORDER MARKET, BY GEOGRAPHY, 2019 – 2028 (USD MILLION)
FIGURE 23 PENNSYLVANIA AUTISM SPECTRUM DISORDER MARKET SNAPSHOT
FIGURE 24 CALIFORNIA AUTISM SPECTRUM DISORDER MARKET SNAPSHOT
FIGURE 25 TEXAS AUTISM SPECTRUM DISORDER MARKET SNAPSHOT
FIGURE 26 NEW YORK AUTISM SPECTRUM DISORDER MARKET SNAPSHOT
FIGURE 27 FLORIDA AUTISM SPECTRUM DISORDER MARKET SNAPSHOT
FIGURE 28 ILLINOIS AUTISM SPECTRUM DISORDER MARKET SNAPSHOT
FIGURE 29 OHIO AUTISM SPECTRUM DISORDER MARKET SNAPSHOT
FIGURE 30 GEORGIA AUTISM SPECTRUM DISORDER MARKET SNAPSHOT
FIGURE 31 MICHIGAN AUTISM SPECTRUM DISORDER MARKET SNAPSHOT
FIGURE 32 NEW JERSEY AUTISM SPECTRUM DISORDER MARKET SNAPSHOT
FIGURE 33 THE U.S. AUTISM SPECTRUM DISORDER MARKET SNAPSHOT\
FIGURE 1 KEY STRATEGIC DEVELOPMENTS
FIGURE 2 UPMC: COMPANY INSIGHT
FIGURE 3 UPMC: SWOT ANALYSIS
FIGURE 4 THE MAY INSTITUTE: COMPANY INSIGHT
FIGURE 5 THE MAY INSTITUTE: SWOT ANALYSIS
FIGURE 6 CHANCE LIGHT BEHAVIORAL HEALTH: COMPANY INSIGHT
FIGURE 7 CHANCE LIGHT BEHAVIORAL HEALTH: SWOT ANALYSIS
FIGURE 8 MAGELLAN HEALTH, INC.: COMPANY INSIGHT
FIGURE 9 MAGELLAN HEALTH, INC.: BREAKDOWN
FIGURE 10 VISTA AUTISM SERVICES: COMPANY INSIGHT
FIGURE 11 OTSUKA HOLDINGS CO. LTD.: COMPANY INSIGHT
FIGURE 12 ELI LILLY AND COMPANY: COMPANY INSIGHT
FIGURE 1 ELI LILLY AND COMPANY: BREAKDOWN
FIGURE 2 PFIZER INC.: COMPANY INSIGHT
FIGURE 3 JOHNSON & JOHNSON: COMPANY INSIGHT
FIGURE 4 JOHNSON & JOHNSON: BREAKDOWN
FIGURE 5 AUTISM SPEAKS: COMPANY INSIGHT
FIGURE 6 CITY PRO GROUP: COMPANY INSIGHT
FIGURE 7 AUTISM LEARNING PARTNERS: COMPANY INSIGHT
FIGURE 8 AUTISM SPECTRUM THERAPIES: COMPANY INSIGHT
FIGURE 9 BUTTERFLY EFFECTS: COMPANY INSIGHT
FIGURE 10 CENTRIA AUTISM SERVICES: COMPANY INSIGHT
FIGURE 11 ALLERGAN: COMPANY INSIGHT
FIGURE 12 THE CENTER FOR AUTISM & RELATED DISORDERS: COMPANY INSIGHT